Product Overview
[Drug Name]
Generic Name: Polycarbophil Calcium Tablets
Trade Name: LiBoFei Polycarbophil Calcium Tablets 0.5g*18 Tablets
Pinyin Full Code: LiBoFei JuKaBoFeiGaiPian 0.5g*18 Tablets
[Main Ingredients]
Main ingredient: Polycarbophil calcium.
[Properties]
This product is a white capsule-shaped tablet.
[Indications/Main Functions]
For constipation, such as chronic constipation, irritable bowel syndrome, diverticular disease, and constipation in pregnant women, the elderly, and patients in recovery. It can also be used for watery diarrhea.
[Specifications]
0.5g*18 tablets
[Dosage and Administration]
Oral. The usual adult dose is two tablets (1.0g) three times a day. Take with plenty of water after meals. The typical course of treatment does not exceed two weeks.
Adverse Reactions:
1. Common (1% to 10%, inclusive) and rare (0.1% to 1%, inclusive) adverse reactions that may occur with this product include: digestive system reactions such as: fever, vomiting, thirst, abdominal distension, diarrhea, constipation, abdominal pain, and bowel sounds; allergic reactions (such as: rash, itching); hematologic reactions (such as: leukopenia); liver and kidney dysfunction (such as: elevated serum alanine aminotransferase (ALT) and serum aspartate aminotransferase, urine occult blood, positive urine protein, edema, and headache). 2. In pre-marketing clinical trials conducted in Japan with 751 subjects, adverse reactions occurred in 54 cases (7.19%), including nausea and vomiting in 13 cases (1.73%), rash in 10 cases (1.33%), thirst in 9 cases (1.20%), edema in 6 cases (0.8%), and pruritus in 5 cases (0.67%). In addition, abnormal changes in laboratory values were observed in patients, including an increase in ALT (1.17%) (5/427), positive urine occult blood test results (0.78%) (2/25), positive proteinuria (0.62%) (2/321), and a decrease in leukocytes (0.47%) (2/423).
[Contraindications]
This product is contraindicated in the following patients: 1. Patients with acute abdominal illness (appendicitis, intestinal bleeding, ulcerative colitis). 2. Patients at risk of postoperative intestinal obstruction. 3. Patients with hypercalcemia. 4. Patients with kidney stones. 5. Patients with renal insufficiency (except for mild renal insufficiency and patients undergoing dialysis). 6. Patients with a history of hypersensitivity to the active ingredient of this drug.
[Drug Interactions]
1. Active vitamin D preparations (such as alphacalcidol and calciferol) promote intestinal calcium absorption and may cause hypercalcemia when used concomitantly with this product. 2. Calcium preparations (such as calcium L-aspartate, calcium lactate, etc.) taken together with this product may lead to excessive calcium intake and cause this product to recombine with calcium ions in a decalcified state, thereby reducing the efficacy of this product. 3. This product may enhance the effects of cardiac glycosides such as digoxin, leading to arrhythmia. 4. This product may form chelates with tetracycline antibiotics (tetracycline, minocycline, etc.) and quinolone antibiotics (norfloxacin, pefloxacin hydrochloride, tosufloxacin tosylate, etc.), affecting the absorption of antibiotics and reducing their efficacy. 5. Proton pump blockers (omeprazole, lansoprazole, etc.), H2 receptor antagonists (famotidine, ranitidine, etc.), and antacids (aluminum hydroxide, magnesium hydroxide, etc.) may increase the pH value in the stomach, inhibit the decalcification of this product, and thus reduce its efficacy.
【Precautions】
1. Important reminder: (1) This product is only used for symptomatic treatment. (2) If symptoms do not improve after using this product, discontinue use (usually within 2 weeks). (3) The safety and efficacy of long-term use of this product have not been confirmed. 2. The following patients should use this product with caution: (1) Patients taking active vitamin D (prone to hypercalcemia). (⑵2) Patients taking cardiac glycosides (may increase the effect of cardiac glycosides). (3) Patients prone to hypercalcemia (may develop hypercalcemia). (4) Patients diagnosed with gastric achlorhydria and with a history of gastrectomy (may find it difficult to fully exert the drug's effect). (5) Patients on dialysis and with mild renal insufficiency (may aggravate renal tissue calcification). Please read the instructions carefully and use as directed by your doctor.
[Drug Use in Children]
The safety of this product for children has not been confirmed and is not recommended.
[Drug Use in Elderly Patients]
In general, most elderly people have low renal function and are prone to hypercalcemia. When using this product, the dose should be reduced or adjusted carefully.
[Overdose]
Not yet clear. [Pharmacology and Toxicology]
This product decalcifies to form polycarbophil under the acidic conditions of the stomach. In the neutral environment of the small or large intestine, it exhibits high water absorption and expands into a gel, retaining moisture in the digestive tract and regulating the transport of digestive tract contents, thereby exerting a therapeutic effect on constipation.
